Track KURA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Kura Oncology Inc
4930 Directors Place, San Diego, CA, United States, 92121
IPO
2015
Employees
260
Industry
Biotechnology
Sector
Healthcare
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20266-6
0
Q4 20256-6
0
Q3 20256-5
1
Q2 20251-1
0
4-quarter cumulative
19 sells1 buys
Analyst Ratings
5 analysts covering
Buy60%recommend buy
Buy
3
Hold
2
Sell
0